ThreoTech to feature highly bioavailable magnesium Magtein at FiE 2025
Key takeaways
- ThreoTech will spotlight its patented bioavailable magnesium L-threonate, Magtein, at FiE 2025, highlighting its ability to cross the blood-brain barrier.
- Magtein received EU Novel Food approval in 2024, with ThreoTech holding exclusive European marketing rights for Magtein for a period of five years.
- The company notes a growing demand for bioavailable magnesium solutions amid heightened consumer focus on cognitive health, stress management, and sleep.
At the upcoming Food ingredients Europe trade show in Paris, France (Dec 2–4), ThreoTech will showcase its patented Magtein, a proprietary form of magnesium L-threonate. The company notes the ingredient supports brain health by effectively crossing the blood-brain barrier.
According to ThreoTech, magnesium is one of the most popular supplements in Europe due to its association with a range of consumer needs, including improving cognition, memory, and sleep, as well as reducing stress.
“Europe is enjoying a magnesium boom, partly because of the growing focus on solutions for cognitive health, sleep, and stress,” says Rory Lipsky, senior VP Marketing at ThreoTech.
“Amid this interest, the choice of which magnesium to include in your product is critical, especially because most products are characterized by poor bioavailability. Magtein is a smarter magnesium supported by science, and we love the fact that we’re now able to offer its unique benefits to the European market.”
Bioavailable mineral
ThreoTech claims that most commercially available forms of magnesium struggle to deliver real benefits for cognition. To improve the mineral’s bioavailability, US researchers combined it with threonate, resulting in a patented molecular structure that facilitates the entry of magnesium into the brain through glucose transporters.
The ingredient supplier AIDP brought the mineral to market as Magtain. ThreoTech is the exclusive global ingredient supplier and patent licensee for the ingredient.
ThreoTech says Magtain has been found to support “better memory, cognition, mood, sleep, and cognitive lifespans.”
After successful sales in the US, Magtain achieved Novel Food approval in the EU last year. AIDP and ThreoTech received exclusive marketing rights for five years.
Magtain can be used in nutraceuticals and a wide range of food and beverage products, such as ready-to-drink beverages, snack bars, gummies, and gels. The ingredient will be on display at ThreoTech’s booth 71P45.
Magnesium developments
As one of the fastest-growing minerals in the supplement industry, magnesium is undergoing transformations that support innovative applications. A significant focus in these developments is to improve magnesium bioavailability and absorption, such as with Balchem’s chelated minerals.
At the recent CPHI trade show for the nutraceutical and pharmaceutical industries in Frankfurt, Germany, Sirio launched a new magnesium portfolio with different dosage forms to target specific health benefits.
ThreoTech also presented Magtain at this event, while Dr. Paul Lohmann highlighted its new LomaChelate Magnesium, which has high bioavailability and fewer gastrointestinal side effects compared to non-reacted magnesium forms.
Meanwhile, the US Council for Responsible Nutrition has raised its recommended safe upper level for magnesium supplements from 400 mg to 500 mg daily for healthy adults. The organization cited new human clinical data on magnesium safety evidencing this claim.
